London Stock Exchange celebrates Hikma Pharmaceuticals 20th anniversary

The London Stock Exchange is pleased to congratulate Hikma Pharmaceuticals on the milestone of its 20-year anniversary as a London-listed company.

Founded in Amman in 1978, Hikma has remained committed to bringing high-quality medicines to patients by providing better access to a broad range of generic, specialty and branded pharmaceutical products. Over the past four decades, the business has evolved into a global healthcare company serving North America, Europe and the Middle East & North Africa, advancing its mission to help shape a healthier world.

The team celebrating on the balcony at LSEG during the welcome ceremony.

During its two decades on the London market, Hikma has delivered consistent and profitable growth, creating long-term value for shareholders through strong returns on investment, driven by product launches, targeted acquisitions and strategic partnerships, alongside expansion of its manufacturing footprint and strengthening of its R&D capabilities. Today the company operates 29 manufacturing plants, nine R&D centres and employs approximately 9,500 people, producing more than 800 products that serve hospitals, physicians and pharmacists across its core markets. Hikma has reinforced its position as a leading supplier of generic injectables in the US and as a major pharmaceutical provider across the MENA region, while further extending its manufacturing capacity in key geographies and building its commercial presence in Europe.

The London Stock Exchange recognises Hikma’s sustained progress since listing, its delivery against strategic priorities and its contribution to both global healthcare and the UK capital markets. We extend our sincere congratulations on this milestone and look forward to the company’s continued development and impact.

“We are proud to mark 20 years of being listed on the London Stock Exchange. This milestone reflects the enduring commitment of our people, the trust of our investors, and our dedication to manufacturing high-quality medicines in our markets. Looking ahead, we remain focused on innovation, operational excellence and sustainable growth to continue creating value for our shareholders and advancing our purpose.”

Said Darwazah
Executive Chairman, Hikma Pharmaceuticals

Useful links

Check out what's happening at the Exchange

Looking to find out more about accessing capital?

If you'd like to find out more about accessing capital, please submit your details and a member of our team will be in touch.

By submitting this form, you agree to your personal data being shared within the London Stock Exchange Group of companies (LSEG) for the purpose of receiving communications via post, phone and electronic means from LSEG about events, resources, products, and/or services.

For more information on how LSEG uses your data, see our privacy statement. You can adjust your preferences at any time through the preference link in any electronic communication that you receive from us.